Alan Feldstein to Present During Upcoming AHPA Webinar
Session will Address Emerging CGMP Compliance Issues
Alan Feldstein, Esq., of Counsel to CGMB and an integral part of the firm’s growing dietary supplements division, will be a featured presenter at an upcoming live webinar hosted by the American Herbal Products Association (AHPA). The AHPA Webinar — “FDA Inspection Trends, cGMP Compliance Issues and Responding to an FDA 483” — is a two-part webinar bringing together veteran legal experts in the industry to address current issues surrounding Good Manufacturing Practice regulations (21 CFR 111), and discuss today’s most critical issues for businesses in the dietary supplement industry surrounding FDA compliance.
The AHPA webinars will take place on November 30th and December 14th, from 1 p.m. until 3 p.m. For additional information about the presentations, and to register for the webinars, click here: http://ahpa.org/News/LatestNews/tabid/96/artmid/1179/articleid/869/Default.aspx.
The webinars are designed to help businesses in the dietary supplement industry understand the elements of current Good Manufacturing Practice regulations that have been the primary focus of recent FDA inspections. This knowledge will help businesses effectively allocate compliance resources. In addition, the webinars will provide data on recent FDA inspections, an overview of emerging compliance issues and strategies for responding to an FDA 483 in order to avoid an FDA Warning Letter.
Specific areas of focus for each webinar include:
- Part One (November 30th): Veteran legal experts in the industry will offer an insider’s view of what FDA has been focusing on regarding cGMPs. This will be done by offering detailed analysis of AHPA’s repository of inspection data, which includes actual FDA 483 inspection reports, observation forms, and establishment inspection reports. Part one will be followed by a 20-30-minute Q&A session where attendees can ask specific questions.
- Part Two (December 14th): This webinar will offer an extended question and answer session that will give attendees the opportunity to have any questions from Part One answered by the veteran legal panel. Part Two will also give attendees tips on how to conduct an FDA inspection, which is crucial for every supplement company. Also, Part Two will focus on providing effective strategies to respond to an FDA 483 – which can prevent your company from receiving an FDA Warning Letter, which is publicly posted on the FDA’s website.
We hope you’ll join us for this important webinar addressing so many critical topics facing supplement companies today. To register, click here – or call us at 516-294-0300 for more information. As always, call us or email us anytime to discuss any questions you may have surrounding the latest news on dietary Good Manufacturing Practices and the dietary supplements industry, and how to ensure FDA compliance in today’s complex times.